ASCO Annual Meeting | Conference

Cabozantinib (XL184) Demonstrates Antitumor Activity and Reduces or Eliminates Bone Metastases in Multiple Cancers

May 18th 2011

Cabozantinib (XL184), an investigational oral tyrosine kinase inhibitor, demonstrated antitumor activity in multiple types of advanced solid tumors.

Study Results Show Ovarian Cancer Deaths Are Not Reduced by Early-Detection Screening Methods

May 18th 2011

The risk of dying from ovarian cancer was not reduced when women received CA-125 blood testing and transvaginal ultrasound

Study Confirms Extending Testing to Every 3 Years in Women Who Test Negative for the HPV Virus

May 18th 2011

A large-scale study of HPV testing and Pap smear for cervical cancer screening confirms that women can safely extend screening intervals from 1 to 3 years.

PSA Found to Be Highly Predictive of Long-Term Risk of Death From Prostate Cancer

May 18th 2011

Prostate-specific antigen (PSA) levels can accurately predict the risk of developing metastasis or death from prostate cancer up to 30 years later

Among Women at High Risk for Breast Cancer, Study Finds Smoking, Not Moderate Alcohol Use, Increases Risk of Common Cancers

May 18th 2011

A prospective study analyzed the risk of contracting common cancers based on baseline self-reporting data on smoking, alcohol use, and physical activity

Stay tuned for Live Conference Coverage from ASCO 2011

May 18th 2011

ASCO 2011, June 3-7, 2011 McCormick Place, Chicago, IL

x